Oramed Pharmaceuticals sell StockNews.com
Start price
04.01.25
/
50%
€2.33
Target price
04.01.26
-
Performance (%)
-22.99%
Price
07:33
?
Summary
This prediction is currently active. The price of Oramed Pharmaceuticals has decreased since the start of the prediction. Compared to the start price this results in a performance of -22.99%. This prediction currently runs until 04.01.26. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this predictionOramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Oramed Pharmaceuticals | -0.556% | -0.556% |
| iShares Core DAX® | 0.130% | 3.439% |
| iShares Nasdaq 100 | -0.443% | 4.555% |
| iShares Nikkei 225® | 0.350% | 0.350% |
| iShares S&P 500 | -0.203% | 3.724% |
Comments by StockNews_com for this prediction
In the thread Oramed Pharmaceuticals diskutieren
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ORMP provided by MarketBeat